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ABSTRACT
Background The rise in electronic cigarette use by
smokers may be responsible for the decreased use of
licensed nicotine products and/or increased overall use of
non-tobacco nicotine-containing products. This paper
reports ﬁndings from the Smoking Toolkit Study (STS)
tracking use of electronic cigarettes and licensed nicotine
products to address this issue.
Methods Data were obtained from monthly surveys
involving 14 502 cigarette smokers in England between
March 2011 and November 2014. Smokers were asked
about their use of electronic cigarettes and licensed
nicotine products.
Results Prevalence of electronic cigarette use increased
rapidly from 2.2% (95% CI 1.4% to 3.2%) in quarter 2
of 2011 to 20.8% (95% CI 18.3% to 23.4%) in quarter
3 of 2013, after which there was no change. Prevalence
of licensed nicotine product use in smokers remained
stable from quarter 2 of 2011 (17.4%, 95% CI 15.3%
to 19.8%) to quarter 3 of 2013 (17.9%, 95% CI
15.62% to 20.5%), and thereafter declined steadily to
7.9% (95% CI 6.0% to 10.4%). Prevalence of use of
any product was stable to quarter 1 of 2012, after
which it increased from 18.5% (95% CI 16.3% to
21.0%) to 33.3% (95% CI 30.4% to 36.3%) in quarter
3 of 2013, and then decreased to 22.7% (95% CI
19.3% to 26.3%).
Conclusions The shapes of trajectories since 2011
suggest that electronic cigarettes are probably not
responsible for the decline in use of licensed nicotine
products. Electronic cigarettes appear to have increased
the total market for use of non-tobacco nicotine-
containing products.
INTRODUCTION
Electronic cigarettes are battery-powered devices
that can provide inhaled doses of nicotine by way
of a vaporised solution. Since they were introduced
to the European market in 2006, there has been
substantial growth in their use by smokers.1
Supermarket sales data showed a rise of over 40%
in their use between 2013 and 2014.2 In contrast,
licensed nicotine products appear to have become
less popular, with sales in many European countries
having decreased over the past few years (eg,
France and the UK).3 4
The use of licensed nicotine products for
smoking reduction appears to promote quit
attempts.5 Thus if electronic cigarette use is substi-
tuting for licensed nicotine product use among
smokers, and does not promote cessation, there
could be a negative net effect on public health. On
the other hand, if electronic cigarette users are pri-
marily smokers who would have tried to reduce
without any nicotine product use or not tried to
reduce at all, there may be a public health gain, as
long as electronic cigarette use also promotes subse-
quent cessation. Although electronic cigarettes are
almost certainly considerably safer than traditional
cigarettes, and when used for cessation they prob-
ably improve the chances of success,1 6 7 evidence
on the beneﬁts or otherwise of electronic cigarette
use while continuing to smoke is mixed.1 6–11
It is therefore important to determine how far
electronic cigarette use has replaced or supplemen-
ted licensed nicotine product use. The introduction
of new smoking cessation aids on to the market has
previously resulted in more smokers using medica-
tions of some sort to help them stop.12 13
However, this may not be the case for electronic
cigarettes and smoking reduction. To address the
Key messages
What is the key question?
▸ Has the rapid rise in the use of electronic
cigarettes by smokers led to the decline in the
use of licensed nicotine products?
What is the bottom line?
▸ The shapes of the trajectories of the use of
electronic cigarettes and licensed nicotine
products suggest that growth in the use of
electronic cigarettes is probably not responsible
for the decline in licensed nicotine product use
by smokers but instead appears to have
increased the market for non-tobacco
nicotine-containing products.
Why read on?
▸ This study provides the ﬁrst evidence in any
country assessing the potential trade-off
between the use of electronic cigarettes and
nicotine products licensed by medicines
regulators.
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issue of how far electronic cigarettes are complementing
licensed nicotine products or replacing them, one can assess
whether the temporal trajectories in prevalence of use of the
two types of product mirror each other. If they follow very dif-
ferent patterns of change, then it is unlikely that they are con-
nected. Therefore, this study set out to answer the following
questions:
1. What has been the trajectory in growth of electronic cigar-
ette use in current smokers, and how has this compared with
the trajectory in decline in use of licensed nicotine products?
2. What has been the resultant trajectory in use of any nicotine-
containing product?
METHODS
Design
The study formed part of the Smoking Toolkit Study (STS), an
ongoing population study designed to provide information on
smoking and smoking cessation patterns among smokers and
recent ex-smokers in England. Data for this paper were obtained
between March 2011 and August 2014. The STS involves
monthly household surveys using a random location sampling
design, with initial random selection of grouped output areas (con-
taining 300 households), stratiﬁed by ACORN (socio-
demographic) characteristics http://acorn.caci.co.uk/ and region.
Interviewers then choose which houses within these areas are most
likely to fulﬁl their quotas and conduct face-to-face computer-
assisted interviews with one member per household.14 Participants
in the STS appear to be representative of the population in
England, having a similar socio-demographic composition to
other large national surveys, such as the Health Survey for
England.14
Measures
Smokers were asked:
1. ‘Are you using any of the following either to help you stop
smoking, to help you cut down or for any other reason at
all?’ Answer: nicotine patch; nicotine gum; nicotine
lozenges/tablets; nicotine inhaler; nicotine nasal spray;
mouth spray; electronic cigarettes; I don’t know; none of
these; other
Smokers were also asked if they were attempting to cut down
their cigarette consumption and:
1. ‘Which, if any, of the following are you currently using to
help you cut down the amount you smoke?’ Answer: nico-
tine patch; nicotine gum; nicotine lozenges/tablets; nicotine
inhaler; nicotine nasal spray; mouth spray; electronic cigar-
ettes; I don’t know; none of these; other
2. ‘Do you regularly use any of the following in situations
when you are not allowed to smoke?’ Answer: nicotine
patch; nicotine gum; nicotine lozenges/tablets; nicotine
inhaler; nicotine nasal spray; mouth spray; electronic cigar-
ettes; I don’t know; none of these; other
Respondents were classiﬁed accordingly:
A. Using electronic cigarettes: reported using electronic cigar-
ettes in response to question 1 and/or 2 and/or 3
B. Using licensed nicotine products: reported using any of the
licensed products in response to question 1 and/or 2 and/or 3
C. Using nicotine-containing products: reported using licensed
nicotine products and/or e-cigarettes in response to question
1 and/or 2 and/or 3.
Contextual information was also gathered on socio-
demographic and smoking-related characteristics (ie, gender,
age, socio-economic status, cigarette consumption, cigarette
dependence, daily versus non-daily nicotine-containing product
use, attempts to quit smoking in the previous 12 months and
attempts to cut down cigarette consumption). Socio-economic
status was measured using the Social-Grade Classiﬁcation
Tool,15 which categorises individuals into one of ﬁve social
grades: AB, C1, C2, D and E. Grades AB and C1 were classiﬁed
as ‘non-manual’ and Grades C2 to E were classiﬁed as ‘manual’
occupational groups. Cigarette dependence was assessed using
time to ﬁrst cigarette of the day.16 A copy of the questionnaire is
available on the STS website (http://www.smokinginengland.
info)
Statistical analysis
Analyses were undertaken using R V.3.1.1. Data were weighted
to match the population in England (see Fidler et al14 for
details). Differences in socio-demographic and smoking
characteristics as a function of nicotine-containing product use
were assessed with generalised linear models (for normally dis-
tributed outcomes) and χ2 tests (for dichotomous outcomes),
using the ‘Survey’ R package.17 Post hoc analyses were con-
ducted using multiple χ2 and t tests, and were adjusted using the
Benjamini and Yekutieli false discovery rate.
Data were aggregated into quarters to reduce the sampling
variation associated with each data point. Trends in prevalence
of use of electronic cigarettes, licensed nicotine products and
nicotine-containing products were ﬁrst assessed using general-
ised linear models (specifying the binomial family and logit link
function). However, as it was hypothesised that the trends may
be inconsistent over time (eg, there may be an initial increase
then decrease in prevalence or vice versa), segmented regression
models were also applied. These are regression models where
the relationship between the outcome and the predictor vari-
ables are piecewise linear, namely represented by at least two
straight lines connected at ‘breakpoints’. For this paper, a break-
point would occur when there was a change in the slope of the
function relating prevalence to time. Segmented regressions
were applied using the ‘segmented’ package,18 which allows
both single and multiple breakpoints to be speciﬁed. This pro-
gramme uses an iterative procedure whereby only starting values
for the breakpoints are required. It also implements bootstrap
restarting to make the algorithm less sensitive to starting values.
To determine whether a model with breakpoints provided a
better ﬁt than a standard generalised linear model, the Davies
test assessed the null hypothesis that there was no difference in
slopes before and after a breakpoint. In all cases, the difference
in slopes was signiﬁcantly greater than 0. As recommended for
segmented regression analyses, the Bayesian Information
Criterion was used to select the optimal number of breakpoints
(ie, 1, 2 or 3).19
Because time is a predictor in the regression analyses, error
terms of consecutive observations may be correlated. This may
lead to underestimation of SEs and overestimation of statistical
signiﬁcance.20 The presence of correlations between consecutive
time points was assessed using the Durbin-Watson statistic.
Based on a critical value of 2.0, there was no evidence of signiﬁ-
cant autocorrelation (values ranged from 1.91 to 1.97).
There were missing data for four of the socio-demographic
and smoking characteristic variables. For frequency of licensed
nicotine product and/or electronic cigarette use, missing data
ranged from 7% among electronic cigarette users to 20%
among those using both products, while less than 3% of partici-
pants had missing data on age, previous attempts to quit
smoking and attempts to cut down. Missing data were imputed
using the ‘Amelia 11’ package.21 The number of imputed data
sets was based on the recommendations of Graham et al22 and
2 Beard E, et al. Thorax 2015;0:1–5. doi:10.1136/thoraxjnl-2015-206801
Smoking
group.bmj.com on September 7, 2015 - Published by http://thorax.bmj.com/Downloaded from 
set to 10. Estimates and results from hypothesis testing were
combined using Rubin’s rules.23 STROBE guidelines for the
reporting of observational studies were followed.24
RESULTS
Between March 2011 and November 2014 data were collected
from 14 502 cigarette smokers. Overall, 76% (95% CI 75.3%
to 76.7%) were not using any form of nicotine-containing
product, 9.9% (95% CI 9.4% to 10.4%) were using electronic
cigarettes, 11.6% (95% CI 11.1% to 12.2%) were using
licensed nicotine products, and 2.4% (95% CI 2.2% to 2.7%)
were using both of these types of product.
Table 1 shows the characteristics of participants as a function
of their nicotine-containing product use. Those not using
nicotine-containing products were less likely to be female com-
pared with those using licensed nicotine products (OR 0.81;
χ2=17.23, df=1, p=0.003) and were more likely to be in a
manual job than those using electronic cigarettes (OR=1.30;
χ2=21.80, df=1, p<0.001) and those using licensed nicotine
products (OR=1.18; χ2=10.27, df=1, p=0.035). Those using
licensed nicotine products were older than those not using any
nicotine-containing product (mean difference 0.94; t(12 835)
=4.35, p<0.001) and those using electronic cigarettes (mean
difference 2.21; t(2998)=2.72, p=0.003).
Those not using any nicotine-containing product had lower
odds of reporting that they were attempting to cut down com-
pared with those using electronic cigarettes (OR 0.27;
χ2=607.12, df=1, p<0.001), those using licensed nicotine pro-
ducts (OR 0.18; χ2=762.93, df=1, p<0.001) and those using
both products (OR 0.12; χ2=231.23, df=1, p<0.001). Those
using licensed nicotine products had higher odds than those
using electronic cigarettes (OR 1.48; χ2=28.22, df=1,
p<0.001) of having made a quit attempt and electronic cigarette
users had higher odds than those not using any product (OR
3.78; χ2=587.86, df=1, p<0.001). Those using both products
were more cigarette dependent than those using only licensed
nicotine products or electronic cigarettes (mean difference 0.11;
t(1663)=3.29, p=0.020 and mean difference 0.18; t(1975)
=2.73, p=0.005, respectively), while those not using any
nicotine-containing product had lower cigarette dependence
compared with those using electronic cigarettes, those using
licensed nicotine products and those using both products (mean
difference 0.09; t(12 523)=2.71, p=0.020, mean difference
0.07; t(12 834)=4.19, p<0.001, and mean difference 0.11;
t(11 500)=5.08, p<0.001, respectively). There was no differ-
ence among groups in the percentage reporting non-daily
smoking (χ2=3.22, df=3, p=0.463). Of those using some form
of nicotine-containing product, those using both electronic
cigarettes and licensed nicotine products were less likely to
report daily use of electronic cigarettes and/or licensed nicotine
products compared with those using electronic cigarettes only
(OR 2.22; χ2=9.75, df=1, p=0.020). Those using both pro-
ducts also had higher odds of reporting that they were doing so
during temporary abstinence relative to electronic cigarette users
(OR 1.50; χ2=7.38, df=1, p=0.026), who had a higher odds
of reporting they were using electronic cigarettes for temporary
abstinence compared to those using licensed nicotine products
only (OR 1.38; χ2=16.81, df=1, p<0.001). There was no dif-
ference among groups in reports of using nicotine-containing
products and/or electronic cigarettes to reduce cigarette con-
sumption (χ2=4.05, df=2, p=0.180).
Figure 1 shows the prevalence of electronic cigarette, licensed
nicotine product and nicotine-containing product use, while
ﬁgure 2 displays the results of the segmented regression ana-
lyses. The segmented regression analyses showed that there was
a rapid increase in electronic cigarette use up to quarter 3 of
2013 from 2.2% (95% CI 1.4% to 3.2%) to 20.8% (95% CI
18.3% to 23.4%) (OR 1.31, 95% CI 1.28% to 1.35%,
p<0.001) and little change thereafter (OR 0.96, 95% CI 0.91%
to 1.01%, p=0.129) with a prevalence in quarter 4 of 2014 of
16.3% (95% CI 13.5% to 19.5%). In contrast, there was no
change in licensed nicotine product use between quarter 2 of
2011 (17.4%, 95% CI 15.3% to 19.8%) and quarter 3 of 2013
(17.9%, 95% CI 15.62% to 20.5%; OR 1.01, 95% CI 0.99 to
1.03, p=0.277); and there was a continual slow decline in
licensed nicotine product use thereafter (OR 0.90, 95% CI 0.84
Table 1 Characteristics of smokers as a function of their use of nicotine-containing products
Not using licensed nicotine
products or electronic cigarettes
Using electronic
cigarettes only
Using licensed nicotine
products only
Using electronic cigarettes and
licensed nicotine products
N=10 431 N=1360 N=1603 N=330
Female % (n) 44.7 (4667)a 48.8 (664) 50.1 (803)b 51.2 (169)
Age mean (SD) 41.5 (17.56)b 41.2 (16.13)b 43.3 (16.17)a 42.5 (15.76)
Manual occupation % (n) 61.7 (6434)a 55.4 (752)b 57.6 (924)b 54.7 (180)
Time to first cigarette mean (SD) 1.3 (1.16)a 1.4 (1.15)b,f 1.5 (1.17)b,f 1.7 (1.11)b,e
Attempts to quit smoking in the
previous 12 months % (n)
23.4 (2452)a 53.7 (729)b 63.2 (1013)c 72.1 (237)c
Non-daily smoking % (n) 10.3 (1077) 11.8 (160) 10.7 (171) 11.6 (38)
Attempting to cut down % (n) 41.7 (4349)a 76.1 (1034)b 77.9 (1248)b 78.5 (259)b
Using nicotine-containing products for
Smoking reduction % (n) NA 69.2 (942) 70.5 (1130) 74.8 (247)
Temporary abstinence % (n) NA 71.4 (971)a 64.4 (1032)b,e 78.9 (260)b,f
Daily nicotine-containing product
use % (n)
NA 56.8 (772)a 52.4 (841) 47.1 (155)b
Data are weighted to match the English population (weighted n’s are presented); n’s were rounded up to the nearest whole number. As a consequence percentages may not sum to
100 and n’s may not sum to total N. Social grade was measured using the social grades system: non-manual includes A: higher managerial, administrative or professional, B:
intermediate managerial, administrative or professional, C1: supervisory or clerical and junior managerial administrative or professional; manual includes C2: skilled manual workers, D:
semi and unskilled manual workers, E: casual or lowest grade workers, pensioners and others who depend on the welfare state for their income. AB and C1 were coded as non-manual
and C2, D and E as manual.17 Time to first cigarette of the day was assessed as (1) >60 min, (2) 31–60 min, (3) 6–30 min or (4) ≤5 min. a, b, c and d all differ; e differs from f. NA,
not applicable.
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to 0.96, p=0.003). The prevalence in quarter 4 of 2014 was
7.9% (95% CI 6.0% to 10.4%).
The result was that there was no increase in nicotine-
containing product use between quarter 2 of 2011 (19.1%, 95%
CI 16.9% to 21.5%) and quarter 1 of 2012 (18.5%, 95% CI
16.3% to 21.0%; OR 0.97, 95% CI 0.91% to 1.04%, p=0.297),
an increase to 33.3% (95% CI 30.4% to 36.3%) up to quarter 3
of 2013 (OR 1.16, 95% CI 1.12 to 1.21, p<0.001) and then a
decrease to 22.7% (95% CI 19.3% to 26.3%) in quarter 4 of
2014 (OR 0.94, 95% CI 0.90 to 0.99, p=0.014).
DISCUSSION
There was a rapid increase in electronic cigarette use by smokers
between quarter 2 of 2011 and quarter 3 of 2013 with little
change thereafter. Over the same period, licensed nicotine product
use remained stable and then dropped gradually between quarter
3 of 2013 and quarter 4 of 2014. The result was an initial growth
in nicotine-containing product use up to quarter 3 of 2013 and a
decrease thereafter. These trajectories suggest that electronic cigar-
ette use is not associated with the reduction in licensed nicotine
product use by smokers but may have instead increased the market
for nicotine-containing products.
If the rise in electronic cigarette use has not been primarily
responsible for the decline in the use of licensed nicotine pro-
ducts by smokers, this raises the question as to what has caused
this decrease. There was no reduction in the percentage of
smokers attempting to reduce their smoking, so that is unlikely
to explain the trend.25 The stop smoking services recommend
licensed nicotine products and offer them on prescription and
use of these services has declined since 2011.26 However, this
decline is unlikely to be an important factor as the large major-
ity of smokers who previously used licensed nicotine products
while smoking had not attended stop smoking services.27
Marketing of licensed nicotine products increased over the
period of data collection, so reduced exposure to advertising
does not appear to be a factor.28 It is possible that the trend
reﬂects a longer term disillusionment with licensed nicotine pro-
ducts as aids to smoking reduction. This is something that war-
rants further investigation.
In terms of what may underlie the trajectory in electronic
cigarette use, the rapid rise could be explained by social conta-
gion with more and more smokers being persuaded that these
products could help them reduce the amount they smoke or
ultimately stop altogether. The plateau could reﬂect a ceiling
on the proportion of smokers who want to reduce their cigar-
ette consumption enough to buy a nicotine product, or it
could be that an increasing proportion of smokers have been
led to believe that electronic cigarettes are as harmful as
tobacco cigarettes,29 thus removing the incentive to use them.
This is another important area for future study.
This study has several strengths including the large number of
participants, the representativeness of the sample and the use of
Figure 1 The proportion of smokers
using nicotine-containing products over
time. Data weighted to match the
English population. E-cigarettes,
electronic cigarettes; LNP, licensed
nicotine product; NCP, nicotine-
containing product. Time is
represented quarterly in years.
Figure 2 The proportion of smokers
using nicotine-containing products over
time: segmented regression results.
Data weighted to match the English
population; E-cigarettes, electronic
cigarettes; LNP, licensed nicotine
product; NCP, nicotine-containing
product. Time represented quarterly
in years.
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frequent sampling. There were also a number of limitations.
This study only considered electronic cigarette and licensed
nicotine product use by current smokers. Use speciﬁcally as an
aid to cessation and use among never and ex-smokers are
important further topics for investigation. Beyond assessing
daily versus non-daily use, this study did not examine the fre-
quency of electronic cigarette and licensed nicotine product use.
This study did not assess to what extent electronic cigarette or
licensed nicotine product use was associated with a reduction in
cigarette consumption or intake of tobacco toxins. Because elec-
tronic cigarette and licensed nicotine product users are likely to
have been heavier smokers before they started using the pro-
ducts, this can only be assessed using prospective designs.1 The
data series was limited to approximately 3 years. It will be
important to continue to monitor the trends to track further
changes as the electronic cigarette market continues to mature
and the regulatory environment changes. As with all survey-
based designs, there is a possibility of misreporting of nicotine-
containing product use although there is no reason to believe
that this varied over time.
In conclusion, the rapid growth in electronic cigarette use
between 2011 and 2013 appears to have increased the overall
market for use of nicotine products while smoking and was not
associated with a decline in use of licensed nicotine products
over this period.
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